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ABSTRACT 
Objectives: To analyse the relationship between AF and Charlson Comorbidity Index 
(CCI) in a population-based cohort study over a long-term follow-up period, in relation to 
oral anticoagulant (OAC) prescriptions and outcomes. 
Patients and Methods: We used data from the administrative health databases of 
Lombardy. All AF patients ≥40 years admitted to hospital in 2002 were considered for 
analysis and followed up to 2014. AF diagnosis and CCI were established according to 
ICD-9 codes. 
Results: In 2002, 24,040 patients were admitted with a diagnosis of AF. CCI was higher in 
AF patients compared to non-AF cases (1.8±2.1 vs. 0.2±0.9, P<.001). Over 12-years of 
follow-up, AF was associated with an increased risk of higher CCI (beta coefficient: 1.69, 
95% confidence interval [CI]: 1.67-1.70). In AF patients, CCI was inversely associated with 
OAC prescription at baseline (P<.001) and at the end of the follow-up (P=.03). AF patients 
with a high CCI (≥4) had a higher cumulative incidence for stroke, major bleeding and all-
cause death (all P<.001), compared to those with low CCI (0-3). Adjusted Cox regression 
analysis found that time-dependent continuous CCI was associated with an increased risk 
for stroke, major bleeding and all-cause death (all P<.001). 
Conclusions: In hospitalized patients, AF is associated with an increase in CCI, that was 
inversely associated with OAC prescriptions during follow-up. CCI is independently 
associated with an increased risk of stroke, major bleeding and all-cause death. 
 
KEYWORDS: atrial fibrillation; multimorbidity; oral anticoagulant drugs; outcomes. 
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INTRODUCTION 
Atrial fibrillation (AF) has an increasing incidence, prevalence and impact on healthcare 
systems globally1.  The worldwide AF epidemic is mainly attributed to an increasing ageing 
population2. AF patients are often older and more affected with concomitant cardiovascular 
(CV) and non-cardiovascular conditions, that affect significantly patients’ clinical course, 
leading to an increased risk of CV and all-cause death3. 
 
The concept of multimorbidity (defined as the concomitant presence of two or more 
chronic conditions) has gained much medical attention in the last decades4. As with AF, 
the prevalence of multimorbidity increases with increasing age and is associated with a 
high risk of mortality, reduced functional status, increased healthcare expenditure and use 
of resources5. As part of the biological, sociological and clinical complexity associated with 
healthcare6, multimorbidity demands solid integrated care and a holistic approach to the 
patient in order to properly manage the associated risks5. Moreover, multimorbidity is very 
common in patients with CV disease7. 
 
The Charlson Comorbidity Index (CCI) has been validated as a reliable tool to evaluate the 
burden of multimorbidity in the general population and is significantly associated with an 
increased risk of all-cause death during the long-term follow-up8. Furthermore, CCI has 
been extensively validated in patients with CV disease9. Nevertheless, despite AF being 
associated with several comorbidities1, scarce data exist about the overall burden of 
multimorbidity and the relationship of CCI with AF. 
 
The aim of this report is to evaluate the relationship between AF, burden of multimorbidity 
(as defined by CCI), the prescription of oral anticoagulant (OAC) drugs and long-term 
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outcomes in a large population-based cohort of AF patients from Lombardy, the largest 
region of Northern Italy. 
 
METHODS 
Data Source and Study Population 
This study used linkable administrative health databases of the Lombardy Region which 
include the demographic data of all residents and detailed information on hospital 
admissions and drug prescriptions. To date, with a population of more than 10 million 
inhabitants, Lombardy is the largest Italian region, comprising highly populated urban 
areas, as well as industrial and rural ones. The Italian healthcare system is based on a 
public National Health Service, which provides free assistance to anyone on the National 
territory, irrespective of any social, economic and clinical pre-existing condition. A personal 
identification code is given to each subject and kept in the National Civil Registration 
System.  
 
All databases are linked anonymously using unique encrypted patient codes, in 
accordance with the Italian privacy regulations. By virtue of a specific agreement between 
the Mario Negri Institute and the Lombardy Region, for the use of the anonymous 
administrative data derived from these databases it was not necessary to obtain approval 
from any ethics committee. Data were available for fifteen consecutive years, from 2000 to 
2014. For any hospital admission, all discharge diagnoses have been coded according to 
International Classification of Disease 9th revision [ICD-9]. Moreover, the hospital 
discharge database records the date of hospital admission, date of discharge or death and 
procedures performed during admission. The drug prescription database contains the drug 
name and its Anatomical Therapeutic Chemical classification code, quantity and 
dispensation date after the discharge at home, but not during the index hospitalization. All 
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data about subjects ≥40 years old (>6 million inhabitants) were available and included in 
this analysis.  
 
Data from 2000 to 2001 were used to build the clinical history of patients and to calculate 
baseline CCI. Year 2002 was used as index year to evaluate AF diagnosis. All discharge 
diagnoses were searched for codes 427.31 and 427.32, and all subjects with these codes 
irrespective of position, were assigned to the group of patients with prevalent AF. A 
random sample of non-AF patients ten times greater than those with AF was taken as a 
control group. 
 
Definition of Concomitant Conditions and CCI Calculation 
According to the diagnoses reported at discharge and coded as per ICD-9, all patients 
were evaluated for presence of concomitant conditions (see Supplementary Materials, 
eTable 1). Hypertension was identified on the basis of prescription of at least one 
antihypertensive drug in the six months after entering the study cohort (see eTable 1 for 
ATC codes). Accordingly, the CHA2DS2-VASc score was computed according to the 
original definitions10. A modified version of HAS-BLED (mHAS-BLED), calculated 
excluding the ‘L’ criterion about quality of oral anticoagulation control, was computed 
according to previous studies11. 
 
In its original definition, CCI comprised 19 diagnosis to which different weights have been 
assigned and summed to obtain the final calculation of CCI8 (eTable 2). For this study, the 
CCI was calculated according to a validated method applied to the administrative 
databases12. All AF patients were grouped according to CCI as patients with low 
multimorbidity (CCI 0-3) and a high multimorbidity (CCI ≥4).  
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In order to analyse the relationship between AF and CCI, we analyzed differences at 
baseline between AF and non-AF patients. Then, we analyzed the relationship between 
AF and CCI throughout the follow-up observation, to establish whether or not a significant 
association exists between AF and increasing multimorbidity burden according to CCI. 
 
Oral Anticoagulant Drugs 
In the purpose of the study we evaluated OAC prescription at baseline and at the end of 
observation according to CCI. At the beginning of observation, only vitamin K antagonists 
(VKAs) were available, while at the end of observation the non-vitamin K antagonist oral 
anticoagulants (NOACs) became available for prescription. OAC drugs prescription were 
recorded as follows: VKA (warfarin: B01AA03, acenocumarol: B01AA07); NOACs 
(dabigatran: B01AE07, rivaroxaban: B01AF01, apixaban: B01AF02, edoxaban: B01AF03), 
antiplatelet drugs (B01AC). Additionally, we evaluated discontinuation of OAC throughout 
the study period and the impact of the burden of multimorbidity in determining the 
occurrence of OAC discontinuation. 
 
Study Outcomes  
Outcomes of interest for the present study were: stroke, major bleeding and all-cause 
death (see Supplementary Materials, Table S1 for ICD-9 codes). Follow-up observation 
started when the patient entered the study cohort and proceeded until one of the outcomes 
occurred or when the follow-up was censored. Reasons to be censored included 
emigration, admission to a nursing home, occurrence of death or reaching the end of the 
follow-up observation. 
 
Statistical Analysis 
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Continuous variables, expressed as mean and standard deviation, were compared across 
the groups using Student’s t-test. Categorical variables, expressed as counts and 
percentages, were compared using Chi-square test.  
 
To analyse the relationship between AF and CCI over the follow-up period, we performed 
a mixed linear effect logistic model adjusted for years of observation, age, sex and an 
interaction term between AF and follow-up years. A supplementary age-stratified analysis 
(<65 years, 65-74 years, ≥75 years) was also performed. 
 
To evaluate the impact of CCI in OAC prescription for AF patients, we performed a logistic 
regression model, adjusted for age and sex, for OAC prescription at baseline and at the 
end of the follow-up. CCI was considered as a continuous variable and as classes (high 
vs. low multimorbidity). At the end of follow-up, we also evaluated separately prescription 
of VKA and NOACs. Impact of CCI in determining OAC discontinuation was evaluated with 
a competitive risk model adjusted for concomitant risk of all-cause death and adjusted with 
age and sex. 
 
Differences in survival between AF patients with low and high multimorbidity were 
analyzed with Log-Rank test and Kaplan-Meier curves were drafted accordingly. A Cox 
regression analysis to evaluate the impact of CCI, considered as a continuous time-
dependent variable, in determining study outcomes was performed. Two Cox regression 
models were performed, as follows: i) adjusted for age and sex; ii) adjusted for age, sex 
and OAC prescription. A two-sided value of p ≤ 0.05 was considered statistically 
significant. Analyses were performed with Stata 13.0 (Stata Corp LP, College Station, TX, 
USA), and SAS software, version 9.4 (SAS Institute). 
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RESULTS 
In 2002, a total of 24,040 AF patients were retrieved, as well as 240,400 non-AF patients. 
At baseline (Table 1), AF patients had a significantly higher mean (±SD) CCI than non-AF 
subjects (1.8±2.1 vs. 0.2±0.9, P<.001). Patients with AF were significantly older and more 
likely male, and more likely affected by comorbidities compared to non-AF subjects. 
Accordingly, AF patients had a significantly higher mean (±SD) CHA₂DS₂-VASc score 
(3.3±1.4 vs. 1.4±1.2, P<.001) and mHAS-BLED (2.3±1.0 vs. 0.9±1.0, P<.001) compared to 
non-AF subjects. 
 
Within the overall AF patient cohort, 4,295 patients (17.9%) had high multimorbidity (CCI 
≥4), while 19,745 (82.1%) had low multimorbidity (CCI 0-3) (Table 1). Mean (±SD) CCI for 
the high multimorbidity group was 5.5±1.8, while for the low multimorbidity group, 1.1±1.1 
(P<.001). Patients with high multimorbidity were older and more likely male than those with 
low multimorbidity (both P<.001). In patients with high multimorbidity all conditions 
considered were more prevalent, except for hypertension which was more prevalent in the 
low multimorbidity group (P<.001). Patients with high multimorbidity had a higher 
thromboembolic risk than the low multimorbidity group (mean [±SD] CHA₂DS₂-VASc score 
4.1±1.5 vs. 3.2±1.3, respectively; P<.001). Similarly, patients with high multimorbidity had 
a higher baseline bleeding risk than those with low multimorbidity (mean [±SD] mHAS-
BLED score 2.8±1.1 vs. 2.1±0.9, respectively; P<0.001). At baseline, patients with high 
multimorbidity were significantly less prescribed with OAC than those with low 
multimorbidity (30.0% vs. 42.3%, P<.001). 
 
Trends in CCI and Relationship with AF 
A mixed linear effect logistic model was compiled to analyse the relationship between AF 
and CCI. Overall, CCI progressively increased over time both in non-AF and AF patients, 
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being increasingly and steadily higher in AF patients compared to non-AF ones (P<.001) 
[Figure 1]. After adjustment for years of observation, age, sex and an interaction term 
between AF and years of observation, AF was associated with a progressively higher CCI 
(beta coefficient: 1.69, 95% confidence interval [CI]: 1.67-1.70), F= 99943.8, P<.001). 
Further, the interaction term between AF and years of observation was also independently 
associated to the progressively higher CCI (P<.001). Subgroup analysis for age classes, 
showed that this relationship was consistently statistically significant for patients <65 
years, 65-74 years and ≥75 years (all P<.001) [eFigures 1-3]. 
 
CCI and OAC Prescription 
After adjustment for age and sex (Table 2), CCI as a continuous variable was inversely 
associated with OAC prescription (odds ratio [OR]: 0.91, 95% CI: 0.89-0.92). The high 
multimorbidity category (CCI ≥4) was inversely associated with OAC prescription (OR: 
0.65, 95% CI: 0.60-0.70).  
 
At the end of follow-up, even though CCI as a continuous variable was inversely 
associated with OAC prescription (OR: 0.98, 95% CI: 0.98-0.99), the high multimorbidity 
category was not significantly associated (OR: 0.98, 95% CI: 0.93-1.04). Examining 
separately VKA and NOACs prescription (Table 2), while there was no difference in VKA 
prescription, both continuous and categorical CCI were inversely associated with 
prescription of NOACs (both P<.001). 
 
Discontinuation of OAC 
Throughout the entire follow-up time, among the 9,646 patients prescribed at baseline with 
an OAC a total of 4,450 (46.1%) discontinued their treatment. Median [IQR] time for 
discontinuation was 3 [1-7] years. In a competitive risk model (adjusted for the competitive 
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risk of death), we verified that increasing CCI (as a time-varying independent variable) 
does not have any impact on risk of discontinuation (hazard ratio [HR]: 1.00, 95% CI: 0.98-
1.01, P=.61), after adjustment for age and sex. 
 
Survival and Regression Analysis 
At follow-up, all the outcomes considered were more likely in the high multimorbidity group 
(eTable 3). Kaplan-Meier analysis shows that risk for stroke, major bleeding and all-cause 
death was consistently higher in high multimorbidity group compared to the low 
multimorbidity group [Figure 2]. 
 
Cox regression analysis (Table 3), using CCI as a continuous time-dependent variable to 
take account of the temporal increase and adjusted for age, sex and use of OAC, CCI was 
significantly associated with an increased risk for stroke (HR: 1.04, 95% CI: 1.02-1.06 per 
increasing point), major bleeding (HR: 1.03, 95% CI: 1.01-1.06 per increasing point) and 
all-cause death (HR: 1.10, 95% CI: 1.09-1.11 per increasing point). 
 
DISCUSSION 
Our study showed that AF patients are exposed to a higher burden of overall 
multimorbidity than non-AF individuals, showing for the first time that a direct relationship 
exist between AF and an increasing multimorbidity burden over long-term follow-up, 
irrespective of age. Second, an increased burden of multimorbidity is inversely associated 
with OAC prescription, which could significantly affect AF patients’ clinical history, despite 
not influencing treatment discontinuation. Third, an increased burden of multimorbidity in 
AF patients is directly and independently associated with an increased risk for stroke, 
major bleeding and all-cause death. 
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The independent relationship between various single diseases and AF has been largely 
demonstrated. Indeed, several conditions contribute independently to incident AF 
occurrence and it has been suggested that tight control of concomitant risk factors and 
comorbidities could significantly reduce the burden of AF13,14. Furthermore, several 
diseases are independently prevalent in AF patients15,16. Our paper first establishes a 
direct link between the presence of AF and the development of a progressively higher 
burden of multimorbidity. The evidence presented allows us to speculate about the role of 
AF as a proxy of a worse clinical status. 
 
Our data are strengthened by the use of a solid and validated tool to evaluate 
multimorbidity such as the CCI. Thus far, data about CCI in the contest of AF are scarce17. 
In a Belgian study derived from a primary care registry, a modified version of the CCI was 
found higher in AF elderly (≥60 years) patients than in non-AF ones, also being associated 
with AF diagnosis17. The data presented in this study extend this previous evidence, 
confirming how the burden of multimorbidity is significant in AF patients, irrespective of 
age and of what may be single medical conditions. In particular, we show how a significant 
proportion of patients (~20%) had a high level of multimorbidity. A recent study derived 
from the UK Biobank, in a cohort of patients with self-reported AF which examined the 
presence of multimorbidity as the additive presence of various conditions, only 19.6% of 
patients reported no comorbidities and 11.1% of patients reported 4 or more 
comorbidities18. 
 
Our results show that increased multimorbidity in AF patients is significantly inversely 
associated with OAC prescription. This is a concerning trend, considering the associated 
increased thromboembolic risk. In the study by Vanbeselaere and colleagues, there was a 
possible inverse relationship between increasing CCI and reduced OAC prescription17. Our 
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study extends previous knowledge, showing how this inverse relationship is consistent in a 
general population and over a long-term observation period. Moreover, we showed that if 
physicians appear to be more confident in prescribing VKA, the prescription of NOACs is 
significantly reduced in patients with increased multimorbidity. Our results substantiate 
previous observations that seem to suggest that AF patients prescribed with NOACs are 
relatively healthier and have less prevalent comorbidities (i.e. coronary artery disease, 
heart failure, pulmonary arterial hypertension, prior stroke) and were likely admitted with 
AF as main diagnosis15,19. Notwithstanding, since the study period included only the initial 
years of NOACs use, this could have influenced the choice of VKA rather than NOACs. 
Also, we cannot exclude that the physiological progressive worsening of renal function did 
influence the preferential choice of VKA in these patients. 
 
In recent years, the increased risk of CV-related and all-cause death in AF cohorts has 
shifted the main focus of prevention of adverse events from stroke to mortality20–25. Our 
data show that the increased and increasing multimorbidity burden is strongly associated 
with an increased risk of all the adverse events, stroke, major bleeding and all-cause 
death. The Framingham Heart Study previously showed that AF patients with 
comorbidities have a consistently increased risk for cardiovascular events and all-cause 
death compared to those without26. An analysis from the “Outcomes Registry for Better 
Informed Treatment of Atrial Fibrillation” study showed that when AF patients were 
clustered according to the more frequent clinical characteristics, those in the ‘low-
comorbidity’ cluster had the lowest risk major cardiovascular and neurological adverse 
events than all the other identified clusters, variously affected by risk factors and other 
comorbidities16. 
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Our report also extends previous knowledge about the usefulness of CCI in AF patients. 
Thus far CCI have been already validated in patients with acute coronary syndrome27 and 
stroke28 and other cardiovascular conditions9. Hence this study represents the first large 
evaluation of CCI in a population-based AF patients’ cohort. 
 
In recent years there has been an increasing need of new approaches to manage AF 
patients, considering them in a more comprehensive, integrated and holistic way. A 
systematic review and meta-analysis by Gallagher and colleagues showed how an 
integrated care approach can significantly reduce hospitalization and mortality in AF 
patients29. Various expert opinions and international consensus statements have proposed 
new integrated models to properly manage AF patients, with the ultimate objective to 
reduce the risk of adverse events30,31. The “Atrial Fibrillation Better Care” (ABC) pathway 
has recently been proposed as a possible model to integrate the various main aspects 
related to AF patients’ management, in order to streamline and facilitate the integrated 
care and the holistic evaluation of these patients32 and showed to be associated with a 
significant lower risk of major adverse events33. Our data support this new approach and 
advocate the need for structured integrated and holistic management of AF patients. 
Adding a routine evaluation of the burden of multimorbidity in AF patients’ clinical 
evaluation could help to identify those patients which would benefit more from integrated 
and holistic management, as described by the ABC pathway, that could reduce the overall 
risk of major adverse events, beyond the “mere” baseline thromboembolic and bleeding 
risk. 
 
Limitations 
The main limitation of this study is related to the use of ICD-9 codes, that even if largely 
validated in clinical research, cannot completely exclude some risk of bias related to 
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inaccuracies and coding mistakes; furthermore, this tool does not allow us to consider and 
evaluate some relevant factors for adverse outcomes in AF patients. Second, since all 
data are retrieved in the frame of hospital admissions, these results need to be cautiously 
generalized to the overall AF population. Nevertheless, administrative data are 
increasingly used in public health research because the information is readily available, 
collected in a standardized way, and inexpensive to use34. Third, using a relatively short 
period of time to build the clinical history and calculate CCI and not having available data 
before 2000, some inaccuracy may lead to some underestimation of CCI. Nevertheless, 
this inaccuracy would affect both the groups considered, hence with a minimal impact in 
terms of the overall results. Furthermore, we did not have any availability of data to 
calculate time in therapeutic range, a pivotal factor in determining major adverse events in 
AF patients treated with VKA35. Lastly, we used an adapted model of CCI conceived for 
the use in health administrative databases12. Despite this, currently the use of adapted CCI 
models to be used in ICD-9 codes-based databases is widely accepted36. Several 
adaptations have been proposed and have been considered similarly accurate and reliable 
in evaluating the burden of multimorbidity and risk of adverse events36. Notwithstanding 
these limitations, we provided the first evidence of a direct relationship between AF and 
increasing burden of multimorbidity and the largest validation of CCI as a reliable tool for 
evaluation of multimorbidity in AF patients and its association with major adverse events. 
 
CONCLUSIONS 
In hospitalized patients, AF is associated with an independent increase in CCI, that was 
inversely associated with OAC prescriptions during follow-up. CCI was independently 
associated with an increased risk of stroke, major bleeding and all-cause death. New 
models of care able to consider the burden of comorbidities in AF patients and offer 
holistic approaches to AF management are needed. 
 17 
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FIGURES LEGENDS 
 
Figure 1: Charlson Comorbidity Index Trends according to Atrial Fibrillation 
Diagnosis 
Legend: Whiskers stand for standard deviation of mean; AF= Atrial Fibrillation; CCI= 
Charlson Comorbidity Index. 
 
Figure 2: Kaplan-Meier Curves for Major Adverse Events according to Charlson 
Comorbidity Index Classes 
Legend: CCI= Charlson Comorbidity Index.  
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Table 1: Baseline Characteristics according to Atrial Fibrillation and Charlson Comorbidity Index 
 Non-AF 
N= 240400 
AF 
N= 24040 
P AF 
 
CCI 0-3 
N= 19745 
CCI ≥4 
N= 4295 
P 
Age, years mean±SD 59.7±13.2 76.1±9.8 <.001 75.7±9.9 77.8±8.8 <.001 
Age classes, n (%) 
 
<.001   <.001 
<65 years 155310 (64.6) 2964 (12.3) 
 
2651 (13.4) 313 (7.3)  
65-74 years 47525 (19.8) 6702 (27.9) 
 
5611 (28.4) 1091 (25.4)  
≥75 years 37565 (15.6) 14374 (59.8) 
 
11483 (58.2) 2891 (67.3)  
Male, n (%) 11096 (46.2) 12079 (50.2) <.001 9841 (49.8) 2238 (52.1) <.001 
Charlson Comorbidity Index, (mean±SD) 0.2±0.9 1.8±2.1 <.001 1.1±1.1 5.5±1.8 <.001 
Hypertension, n (%) 79801 (33.2) 18605 (77.4) <.001 15452 (78.3) 3153 (73.4) <.001 
Diabetes Mellitus, n (%) 4316 (1.8) 3555 (14.8) <.001 1763 (8.9) 1792 (41.7) <.001 
Myocardial Infarction, n (%) 1723 (0.7) 1400 (5.8) <.001 869 (4.4) 531 (12.4) <.001 
Congestive Heart Failure, n (%) 2919 (1.2) 7249 (30.1) <.001 4882 (24.7) 2367 (55.1) <.001 
Cerebrovascular Disease, n (%) 3216 (1.3) 3605 (15.0) <.001 1625 (8.2) 1980 (46.1) <.001 
Hemiplegia, n (%) 2282 (0.9) 2830 (11.8) <.001 1027 (5.2) 1803 (42.0) <.001 
Dementia, n (%) 489 (0.2) 400 (1.7) <.001 197 (1.0) 203 (4.7) <.001 
COPD, n (%) 3125 (1.3) 4017 (16.7) <.001 2523 (12.8) 1494 (34.8) <.001 
Connective Tissue Disease, n (%) 560 (0.2) 303 (1.3) <.001 228 (1.1) 75 (1.7) .002 
Ulcer, n (%) 620 (0.3) 440 (1.8) <.001 287 (1.4) 153 (3.6) <.001 
Mild Liver Disease, n (%) 1918 (0.8) 1212 (5.0) <.001 669 (3.4) 543 (12.6) <.001 
Moderate/Severe Liver disease, n (%) 769 (0.3) 334 (1.4) <.001 44 (0.2) 290 (6.7) <.001 
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Legend: AF= Atrial Fibrillation; CCI= Charlson Comorbidity Index; COPD= Chronic Obstructive Pulmonary Disease; SD= Standard 
Deviation. 
  
Renal Disease, n (%) 1244 (0.5) 2087 (8.7) <.001 788 (4.0) 1299 (30.24) <.001 
Metastatic Tumor, n (%) 1162 (0.5) 503 (2.1) <.001 0 (0.0) 503 (11.7) <.001 
Leukemia, n (%) 117 (0.1) 86 (0.4) <.001 49 (0.2) 37 (0.9) <.001 
Lymphoma, n (%) 305 (0.1) 190 (0.8) <.001 90 (0.5) 100 (2.3) <.001 
Any Tumor, n (%) 4423 (1.8) 2189 (9.1) <.001 1124 (5.7) 1065 (24.8) <.001 
CHA₂DS₂-VASc, (mean±SD) 1.4±1.2 3.3±1.4 <.001 3.2±1.3 4.1±1.5 <.001 
mHAS-BLED, (mean±SD) 0.9±1.0 2.3±1.0 <.001 2.1±0.9 2.8±1.1 <.001 
Oral Anticoagulant Drugs, n (%) 4141 (1.7) 9646 (40.1) <.001 8358 (42.3) 1288 (30.0) <.001 
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Table 2: Logistic Regression Analysis for Oral Anticoagulant Drugs Prescription according to Charlson Comorbidity Index 
 OAC Prescription at Baseline OAC Prescription at End of Follow-Up 
 OR 95% CI P OR 95% CI P 
CCI (as continuous variable) 0.91 0.89-0.92 <.001 0.98 0.98-0.99 .03 
CCI ≥4 (vs. CCI 0-3) 0.65 0.60-0.70 <.001 0.98 0.93-1.04 .50 
 VKA Prescription at End of Follow-Up NOACs Prescription at End of Follow-Up 
 OR 95% CI P OR 95% CI P 
CCI (as continuous variable) 0.99 0.98-1.00 .22 0.86 0.81-0.90 <.001 
CCI ≥4 (vs. CCI 0-3) 1.00 0.95-1.06 .94 0.48 0.37-0.63 <.001 
Legend: CCI= Charlson Comorbidity Index; NOACs= Non-Vitamin K Antagonists Oral Anticoagulants; OAC= Oral Anticoagulants; 
VKA= Vitamin K Antagonist. 
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Table 3: Cox Regression Analysis for Major Adverse Events 
 Charlson Comorbidity Index  
(as continuous time-dependent variable) 
 Model 1* Model 2† 
 HR 95% CI P HR 95% CI P 
Stroke 1.04 1.03-1.06 <.001 1.04 1.02-1.06 <.001 
Major Bleeding 1.02 0.99-1.04 .15 1.03 1.01-1.06 <.001 
All-Cause Death 1.10 1.09-1.11 <.001 1.10 1.09-1.11 <.001 
Legend: *adjusted for sex and age; †adjusted for sex, age and use of OAC; CI= Confidence Interval; HR= Hazard Ratio; OAC= Oral 
Anticoagulant. 
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eTable 1: ICD-9 Codes 
Condition ICD-9/ATC Codes Weight 
Myocardial Infarction 410.xx, 411.xx 1 
Congestive Heart Failure 398.xx, 402.xx, 428.xx 1 
Peripheral Vascular Disease 440.xx-447.xx 1 
Dementia 290.xx, 291.xx, 294.xx 1 
Cerebrovascular Disease 430.xx-433.xx, 435.xx 1 
COPD 491.xx-493.xx 1 
Connective Tissue Disease 710.xx, 714.xx, 725.xx 1 
Ulcer Disease 531.xx-534.xx 1 
Mild Liver Disease 571.xx, 573.xx 1 
Hemiplegia 342.xx, 434.xx, 436.xx, 
437.xx 
2 
Moderate or Severe Renal 
Disease 
403.xx, 404.xx, 580.xx-
586.xx 
2 
Diabetes Mellitus 250.xx 2 
Any Tumor 140.xx-195.xx 2 
Leukemia 204.xx-208.xx 2 
Lymphoma 200.xx, 202.xx, 203.xx 2 
Moderate or Severe Liver 
Disease 
070.xx, 570.xx, 572.xx 3 
Metastatic Solid Tumor 196.xx-199.xx 6 
Hypertension ATC: C02, C03, C07, 
C08, C09 
- 
 30 
Stroke 434.xx, 436.xx - 
Major Bleeding 430.xx, 431.xx, 432.xx, 
459.0, 530.82, 569.3, 
578.xx 
- 
Legend: ATC= Anatomical Therapeutic Classification; COPD= Chronic Obstructive 
Pulmonary Disease; ICD= International Classification of Disease. 
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eTable 2: Charlson Comorbidity Index  
Condition Weight 
Myocardial Infarction 1 
Congestive Heart Failure 1 
Peripheral Vascular Disease 1 
Cerebrovascular Disease 1 
Dementia 1 
COPD 1 
Connective Tissue Disease 1 
Ulcer Disease 1 
Mild Liver Disease 1 
Diabetes Mellitus 1 
Hemiplegia 2 
Moderate or Severe Renal Disease 2 
Diabetes Mellitus with End-Organ 
Damage 
2 
Any Tumor 2 
Leukemia 2 
Lymphoma 2 
Moderate or Severe Liver Disease 3 
Autoimmune Deficiency Syndrome 6 
Metastatic Solid Tumor 6 
Legend: COPD= Chronic Obstructive Pulmonary Disease. 
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eTable 3: Major Adverse Events according to Charlson Comorbidity Index Classes  
 CCI 0-3 
N= 19745 
CCI ≥4 
N= 4295 
p 
 N Cumulative Incidence* N Cumulative Incidence*  
Stroke 1826 17.4 412 26.0 <.001 
Major Bleeding 1120 12.0 197 15.7 <.001 
All-Cause Death 13831 76.0 3650 95.0 <.001 
Legend: *per 100 patients; CCI= Charlson Comorbidity Index. 
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eFigure 1: Charlson Comorbidity Index Trends according to Atrial Fibrillation Diagnosis in Patients <65 years old 
Legend: Whiskers stand for standard deviation of mean; AF= Atrial Fibrillation; CCI= Charlson Comorbidity Index. 
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eFigure 2: Charlson Comorbidity Index Trends according to Atrial Fibrillation Diagnosis in Patients 65-74 years old 
Legend: Whiskers stand for standard deviation of mean; AF= Atrial Fibrillation; CCI= Charlson Comorbidity Index. 
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eFigure 3: Charlson Comorbidity Index Trends according to Atrial Fibrillation Diagnosis in Patients ≥75 years old 
 
Legend: Whiskers stand for standard deviation of mean; AF= Atrial Fibrillation; CCI= Charlson Comorbidity Index. 
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